ArticleRespiratory medicine case reports2022
Management of life-threatening malignant central airway obstruction: A novel approach of using extracorporeal membrane oxygenation with tumor debulking and stenting.
Article in Respiratory medicine case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- International Consensus on Severe Lung Cancer-The Second Edition.Translational lung cancer research · 2026Review
- Article
- Distal central airway obstruction: should preemptive extracorporeal membrane oxygenation be the standard of care?Anaesthesiology intensive therapy · 2024Article
- Management of malignancy-induced, life-threatening hypoxemic respiratory failure using a self-expanding Y stent.Respiratory medicine case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracorporeal membrane oxygenation (ECMO) is an artificial lung or heart used to oxygenate and circulate blood. Veno-venous ECMO is most commonly used as an emergency therapy in patients with acute respiratory distress syndrome (ARDS), but it has the potential to be useful in other respiratory-related diseases. We report a case where ECMO successfully allowed for interventional pulmonary procedures in a patient with life-threatening tracheal obstruction secondary to lung cancer, requiring tumor debulking and silicone Y stent placement. The patient was a 44-year-old male who was admitted to the intensive care unit (ICU) for an advanced stage subcarinal tumor invading into the trachea and bilateral main stem bronchi. The tumor was unresectable, and the first attempt to debulk the tumor was terminated due to the risk of complete airway occlusion. With the help of ECMO, the second attempt at tumor debulking was successful, and a Y stent was placed. The patient regained ventilation in both lungs and was transferred out of the ICU on day 2 post-op. The pathology confirmed squamous cell carcinoma, programmed death-ligand 1 (PD-L1) 99%. The patient received immunotherapy after hospital discharge. ECMO has the potential to be useful for patients with severe tracheal obstructions and compromised respiratory systems. For patients with certain types of lung cancer, who are good candidates for novel immunotherapies and targeted therapies, it offers a potential bridging therapy for procedures that would otherwise be too dangerous and should be considered when traditional treatments for these patients fail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.